Drugs / MUC1-KLH conjugate vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006041 | Feb 2000 → Feb 2002 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006041 ↗ |
| Known as | MUC1-KLH vaccine | “MUC1-KLH vaccine/QS21” NCT00006041 ↗ |
| Modality | Vaccine | “glycosylated MUC-1-KLH vaccine” NCT00006041 ↗ |
| Route | Subcutaneous | “Patients receive glycosylated MUC-1-KLH vaccine and QS21 subcutaneously once a week” NCT00006041 ↗ |